GSSP4 polynucleotides and polypeptides and uses thereof

Details GSSP4 polynucleotides and polypeptides and uses thereof GSSP4 polynucleotides and polypeptides and uses thereof

2007-05-29

2007-05-29

Nickol, Gary (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C514S909000, C530S300000

Reexamination Certificate

active

10467554

ABSTRACT:
The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GSSP4 polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing cholesterol levels, body mass, body fat, and for treating metabolic-related diseases and disorders. The metabolic-related diseases or disorders include, but are not limited to, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, diabetes, glucose intolerance, insulin resistance and hypertension.

REFERENCES:
patent: 4914025 (1990-04-01), Manoil et al.
patent: 5019369 (1991-05-01), Presant et al.
patent: 5376533 (1994-12-01), Maclaren et al.
patent: 5536637 (1996-07-01), Jacobs
patent: 5872141 (1999-02-01), Umbreit et al.
patent: 6034062 (2000-03-01), Thies et al.
patent: 6110490 (2000-08-01), Thierry
patent: 6204060 (2001-03-01), Mehtali et al.
patent: 6242179 (2001-06-01), Shah et al.
patent: 6485938 (2002-11-01), Sheppard et al.
patent: 6913919 (2005-07-01), Botstein et al.
patent: 2003/0059856 (2003-03-01), Ames et al.
patent: 2004/0077535 (2004-04-01), Ohtaki et al.
patent: 2005/0065079 (2005-03-01), Soalia et al.
patent: 625 562 (1994-11-01), None
patent: 1130094 (2000-07-01), None
patent: WO 97/18826 (1995-07-01), None
patent: WO 96/34981 (1996-11-01), None
patent: WO 97/04097 (1997-02-01), None
patent: WO 97/07198 (1997-02-01), None
patent: WO 97/38003 (1997-10-01), None
patent: WO 98/07830 (1998-02-01), None
patent: WO 98/20895 (1998-05-01), None
patent: WO 98/45437 (1998-10-01), None
patent: WO 98/55614 (1998-12-01), None
patent: WO 99/47540 (1999-09-01), None
patent: WO 99/53051 (1999-10-01), None
patent: WO 00/52022 (2000-09-01), None
patent: WO 00/75327 (2000-12-01), None
Ranneries et al, Am. J. Physiology 274: E155-E161, 1998.
Heffernan et al., Am. J. Phys. End. Metab. 279: E501-E507, 2000.
Wells, Biochemistry 29:8509-8517, 1990.
Ngo et al., The protein Folding Problem and Tertiary Structure Prediction, 491-495, 1994.
Abraham, E., et al., “Phosphatidic Acid Signaling Mediates Lung Cytokine Expression and Lung Inflammatory Injury After Hemorrhage in Mice”,J. Exp. Med., 1995, pp. 569-575, vol. 181.
Brindley, D. and Waggoner, D. “Phosphatidate phosphohydrolase and signal transduction”,Chem. Phys. Lipids, 1996, pp. 45-57, vol. 80.
Bursten, S., et al., “Potential Role for Phosphatidic Acid in Mediating the Inflammatory Responses to TNFα and IL-1β”,Circ. Shock, 1994, pp. 14-29, vol. 44.
English, D., “Phosphatidic Acid: A Lipid Messenger Involved in Intracellular and Extracellular Signalling”,Cell. Signal., 1996, pp. 341-347, vol. 8, No. 5.
English, D., et al., “Messenger functions of phosphatidic acid”,Chem. Phys. Lipids, 1996, pp. 117-132, vol. 80.
Kent, C. “Eukaryotic Phospholipid Biosynthesis”,Ann. Rev. Biochem., 1995, pp. 315-343, vol. 64.
Leung, D., et al., “CT-2576, an inhibitor of phospholipids signaling, suppresses constitutive and induced expression of human immunodeficiency virus”,Proc. Natl. Acad. Sci. USA, 1995, pp. 4813-4817, vol. 92.
Rice, G., et al., “Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid”,Proc. Natl. Acad. Sci. USA, 1994, 3857-3861, vol. 91.
Roberts, R. and Morris, A. “Role of phosphatidic acid phosphatase 2a in uptake of extracellular lipid phosphate mediators”,Biochimica et Biophysica Acta, 2000, pp. 33-49, vol. 1487.
Salvador, G.A., et al., “Differential modulation of phospholipase D and phosphatidate phosphohydrolase during aging in rat cerebral cortex synaptosomes”,Exp. Gerontology, 2002, pp. 543-552, vol. 37.
Stukey, J. and Carman, G. “Identification of a novel phosphatase sequence motif”,Protein Science, 1997, pp. 469-472, vol. 6.
Database GENBANK, Accession NP—003702; Pandey, A.V., et al., “Protein phosphatase 2A and phosphoprotein SET regulate androgen production by p450c17”,J. Biol. Chem., 2003, pp. 2837-2844, vol. 278, Issue 5.
Database GENBANK, Accession No. NP—795714; Pandey, A.V., et al., “Protein phosphatase 2A and phosphoprotein SET regulate androgen production by p450c17”,J. Biol. Chem., 2003, pp. 2837-2844, vol. 278, Issue 5.
Database GENBANK, Accession No. NP—803133; Ishikawa, T., et al., “Cell surface activities of the human type 2b phosphatidic acid phosphatase”,J. Biochem., 2000, pp. 645-651, vol. 127, Issue 4.
Database GENBANK, Accession No. NP—808211; Zhang, N., et al., “Mice mutant for Ppap2c, a homolog of the germ cell migration regulator wunen, are viable and fertile”,Genesis, 2000, pp. 137-140, vol. 27, Issue 4.
Accession No. AAB70690, Human hDPP protein sequence SEQ ID No. 7, May 17, 2001.
Jacobs, K. et al. “A Novel Method for Isolating Eukaryotic cDNA Clones Encoding Secreted Proteins”,Dendritic Cells: Antigen Presenting Cells of T and B Lymphocytes, Mar. 10-16, 1995, p. C1-207.
Bougueleret, L. et al., “Extended cDNAs useful for expressing secreted proteins and to obtain specific antibodies”, 2000, pp. 203-204, Accession No. AAY59685.
Cameron, C. et al., “Function and Protective Capacity ofTreponema pallidumsubsp.pallidumGlycerophosphodiester Phosphodiesterase”,Infection and Immunity(1998), pp. 5763-5770, vol. 66, No. 12, American Society for Microbiology.
Downes, G. et al., “Structure and Mapping of the G Protein γ3 Subunit Gene and a Divergently Transcribed Novel Gene,Gng31g”, Genomics(1998), pp. 220-230, vol. 53, Academic Press.
Inoue, S. et al., “Growth Suppression ofEscherichia coliby Induction of Expression of Mammalian Genes with Transmembrane of ATPase Domains”,Biochem. Biophys. Reas. Comm. (2000), pp. 553-561, vol. 268, Academic Press.
Janson, H., et al., “Protein D, the Glycerophosphodiester Phosphodiesterase fromHaemophilus influenzaewith Affinity for Human Immunoglobulin D, Influences Virulence in a Rat Otitis Model”,Infection and Immunity, 1994, pp. 4848-4854, vol. 62, No. 11, American Society for Microbiology.
Larson, T., et al., “Periplasmic Glycerophosphodiester Phosphodiesterase ofEscherichia coli, a New Enzyme of theglpRegulon”,J. Biol. Chem., 1983, pp. 5428-5432, vol. 258, No. 9.
Magré, J. et al., “Identification of the gene altered in Berardinelli-Seip congential lipodystrophy on chromosome 11q13”,Nature Genetics(2001), pp. 365-370, vol. 28.
Meldrum, Brian, “Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology”,The Journal of Nutrition—Supplement(presented at the International Symposium on Glutamate, 1998), 2000, pp. 1007S-1015S, Pub: American Society for Nutritional Sciences.
Munson, R. et al., “Protein D, a Putative Immunoglobulin D-Binding Protein Produced byHaemophilus influenzae, Is Glycerophosphodiester Phosphodiesterase”,J. Bacteriology, 1993, pp. 4569-4571, vol. 175, No. 14.
Neer, Eva, “Heterotrimeric G Proteins: Organizers of Transmembrane Signals”,Cell, 1995, pp. 249-257, vol. 80, Cell Press.
Schoepp, D. et al., “Metabotropic glutamate receptors in brain function and pathology”,TiPS, 1993, pp. 13-20, vol. 14, Elsevier Science Publishers, Ltd., UK.
Zheng, B. et al., MIR16, a putative membrane glycerophosphodiester phosphodiesterase, interacts with RGS16,PNAS, 2000, pp. 3999-4004, vol. 97, No. 8.
Zheng, B. et al., MIR16, a putative membrane glycerophosphodiester phosphodiesterase, interacts with RGS16,Proc. Natl. Acad. Sci. U.S.A. (2000), pp. 3999-4004, vol. 97, No. 8, Accession No. AAF65234 (bases 1 to 331).
Zheng, B. et al., MIR16, a putative membrane glycerophosphodiester phosphodiesterase, interacts with RGS16,Proc. Natl. Acad. Sci. U.S.A. (2000), pp. 3999-4004, vol. 97, No. 8, Accession No. AF212862 (bases 1 to 1200).
Glycerophosphoryl Diester Phosphodi

Affiliated with

Also associated with

Rating

GSSP4 polynucleotides and polypeptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with GSSP4 polynucleotides and polypeptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GSSP4 polynucleotides and polypeptides and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3823640